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ABSTRACT: 
 
Virtual Screening (VS) methods can considerably aid clinical research, predicting how ligands interact 
with drug targets. However, the accuracy of most VS methods is constrained by limitations in the scoring 
function that describes biomolecular interactions, and even nowadays these uncertainties are not 
completely understood. In order to improve accuracy of scoring functions used in most VS methods we 
propose a hybrid novel approach where neural networks (NNET) and support vector machines (SVM) 
methods are trained with databases of known active (drugs) and inactive compounds, being this 
information exploited afterwards to improve VS predictions.  
  
 Keywords: Clinical Research, Computational Intelligence, Drug Discovery, Neural Networks, Support 
Vector Machines, Virtual Screening. 
  
  
1 INTRODUCTION 
In clinical research, it is crucial to determine the safety and effectiveness of current drugs and to 
accelerate findings in basic research (discovery of new leads and active compounds) into meaningful 
health outcomes. Both objectives need to process the large data set of protein structures available in 
biological databases such as PDB [1] and also derived from genomic data using techniques such as 
homology modeling [2]. Screenings in lab and compound optimization are expensive and slow methods, 
but bioinformatics can vastly help clinical research for the mentioned purposes by providing prediction of 
the toxicity of drugs and activity in non-tested targets, and by evolving discovered active compounds into 
drugs during clinical trials.  
This aim can be achieved thanks to the availability of bioinformatics tools and Virtual Screening (VS) 
methods that allow testing all required hypothesis before clinical trials. However, the accuracy of most 
VS methods is constrained by limitations in the scoring function that describes biomolecular interactions, 
and even nowadays these uncertainties are not completely understood. In order to solve this problem we 
propose a novel hybrid approach where Computational Intelligence (CI) methods that include neural 
networks (NNET) and support vector machines (SVM) are trained with databases of known active (drugs) 
and inactive compounds (decoys) and later used to improve VS predictions. Other approaches based on 
the use of molecular descriptors have been previously described in the literature but they were applied in 
concrete contexts of protein-ligand interactions [2-4], while the method we propose can be applied to any 
case of protein-ligand interactions and VS method, provided previous experimental information for active 
and inactive compounds is available.  
The rest of the paper is organized as follows. Section 2 describes the methodology including VS, NNET 
and SVM techniques, and molecular properties used in this study. Section 3 presents the experiments 
carried out to refine the VS methods with the previously mentioned techniques while section 4 reports the 
results obtained. In section 5 we present our main conclusions and further work. 
2  METHOLODOGY 
In this section we describe the methodologies we used for the improved prediction of protein-ligand 
affinities; a) the Virtual Screening method (VS), and b) two different CI techniques are employed that 
include; neural networks (NN) and support vector machines (SVM) trained with different molecular 
properties calculated for known active and inactive compounds selected from standard VS benchmarks. 
In Fig. (1) the flowchart of our experimental setup is depicted. 
 
 
Figure 1. Flowchart of the experimental setup used in this work. 
 
2.1 Virtual Screening  
Essentially, VS methods screen a large database of molecules in order to find compounds that fit some 
established criteria [6]. In the case of the discovery of new leads, compound optimization, toxicity 
evaluation and additional stages of the drug discovery process, we screen a large compound database to 
find a small molecule which interacts in a desired way with one or many different receptors. Among the 
many available VS methods for this purpose one of the most structurally accurate methods is protein-
ligand docking [7, 8]. These methods try to obtain rapid and accurate predictions of the 3D conformation 
a ligand adopts when it interacts with a given protein target, and also the strength of this union, in terms 
of its scoring function value. Docking simulations are typically carried out in a very concrete part of the 
protein surface in methods such as Autodock [9], Glide [10] and DOCK [11], to name a few. This region 
is commonly derived from the position of a particular ligand in the crystal structure, or from the crystal 
structure of the protein without any ligand. The former can be performed when the protein is co-
crystallized with the ligand, but it might happen that no crystal structure of this ligand-protein pair is at 
disposal. Nevertheless, the main problem is to take the assumption, once the binding site is specified, that 
many different ligands will interact with the protein in the same region, discarding completely the other 
areas of the protein. 
In essence, in a docking simulation we calculate the ligand-protein interaction energy for a given starting 
configuration of the system, which is represented by a scoring function [12]. In most VS methods the 
scoring function calculates electrostatic (ES), Van der Waals (VDW) and hydrogen bond (HBOND) 
terms. 
Furthermore, in docking methods it is normally assumed [13] that the minima of the scoring function, 
among all ligand-protein conformations, will accurately represent the conformation the system adopts 
when the ligand binds to the protein. Thus, when the simulation starts, we try to minimize the value of the 
scoring function by continuously performing random or predefined perturbations of the system, 
calculating for each step the new value of the scoring function, and accepting it or not following different 
approaches like the Monte Carlo minimization method [14,15].  
 
2.2 Computational Intelligence Methods 
We describe in this section the CI methods we will apply to refine the prediction capacities of VS. 
2.2.1 Neural Networks 
One of the most dominant application areas of neural networks is non-linear function approximation.  The 
main advantage of neural network modeling is that complex non-linear relationships can be modeled 
without assumptions about the form of the model. That feature is very useful in the field of drug design 
and drug discovery. 
More than two decades ago, the aqueous solubility of organic compounds was studied using neural 
approaches [16]. In next decade, supervised and unsupervised neural models were employed to model 
QSAR, predict molecules activities and structure, clustering and many more [17-18]. More recently the 
problem of drug solubility prediction from structure has been revisited [19]. Properties of organic 
compounds obtained from the molecular structure have been extensively studied using hybrid techniques 
that include neural networks [20-22]. Also identification of small-molecule ligands has been improved 
using neural techniques [23-25]. In the last years a large number of authors have designed hybrid methods 
that combined neural networks with other techniques to solve chemistry related problems.  
There are several types of feed-forward neural networks (NNET), the most widely used being multi-layer 
networks with sigmoidal activation functions (multi-layer perceptrons) and single layer networks with 
local activation functions (radial basis function networks). The good approximation capability of neural 
networks has been widely demonstrated by both practical applications and theoretical research. We 
decided to use a single-hidden-layer neural network with skip-layer connections in this study, as shown in 
Fig. (2), since it has been clearly demonstrated its impact on the differentiation between active and 
inactive compounds and other chemical applications [17]. For such purpose we used the nnet function of 
the R package [26]. 
 
Figure 2. Single Hidden layer Neural Network 
 
2.2.2 Support Vector Machines 
Support vector machines (SVM) [27]  are a group of supervised learning methods that can be applied to 
classification or regression. They represent the decision boundary in terms of a typically small subset of 
all training examples, called the support vectors. In a short period of time, SVM have found numerous 
applications in chemistry, such as in drug design [28] when discriminating between ligands and non-
ligands, inhibitors and non-inhibitors, drug discovery [29], quantitative structure-activity relationships 
(QSAR, where SVM regression is used to predict various physical, chemical, or biological properties) 
[30], chemometrics (optimization of chromatographic separation or compound concentration prediction 
from spectral data as examples), sensors (for qualitative and quantitative prediction from sensor data), 
chemical engineering (fault detection and modeling of industrial processes)[31]. An excellent review of 
SVM applications in chemistry can be found in [32].    
In our case, we exploit the idea that SVM produce a particular hyperplane in feature space that separates 
the active from the inactive compounds called the maximum margin hyperplane, as shown in Fig. (3). 
Most used kernels within SVM technique include: linear (dot), Polynomial, Neural (sigmoid,Tanh), 
Anova, Fourier, Spline, B Spline, Additive, Tensor and  Gaussian Radial Basis or Exponential Radial 
Basis. 
 
 
Figure 3. Support Vector Machines margin hyperplanes 
 
2.3 Ligand databases and molecular properties 
We carried out our study applying the methods described in sections 2.2.1 and 2.2.2 and using different 
sets of molecules that are known to be active or inactive. We employed standard VS benchmark tests, 
such as the Directory of Useful Decoys (DUD) [33], where VS methods check how efficient they are in 
differentiating ligands that are known to bind to a given target, from non-binders or decoys. Input data for 
each molecule of each set contains its molecular structure and whether it is active or not. We focused on 
three diverse DUD datasets (details are shown in Table 1) that cover kinases, nuclear hormone receptors 
and other enzymes such as TK, which corresponds to thymidine kinase (from PDB 1KIM), MR, which 
corresponds to mineralocorticoid receptor (from PDB 2AA2), and GPB, which corresponds to the enzyme 
glycogen phosphorylase (from PDB 1A8I).  
 
 
 
Protein PDB 
Code 
Resolution 
(Å) 
no of  
ligands 
no of  
decoys 
GPB 1A8I 1.8 52 1851 
MR 2AA2 1.9 15 535 
TK 1KIM 2.1 22 785 
 
Table 1. Number of active (ligands) and inactive compounds (decoys) for each of the sets used in this 
study, obtained from DUD [33]. 
 
 
Next, using the ChemoPy package [34] we calculated for all ligands of the TK, MR and GPB sets a 
diverse set of molecular properties derived from the set of constitutional, CPSA (charged partial surface 
area) and fragment/fingerprint-based descriptors, as described in Table 2. Constitutional properties 
depend on very simple descriptors of the molecule that can be easily calculated just counting the number 
of molecular elements such as atoms, types of atoms, bonds, rings, etc. These descriptors should be able 
to differentiate very dissimilar molecules, but might have problem for separating closely related isomers. 
CPSA descriptors take into account finer details of molecular structure, so they might be able to separate 
similar molecules, but might also have difficulties for separating isomers. Lastly, fragment and 
fingerprint-based descriptors take into account the presence of an exact structure (not a substructure) with 
limited specified attachment points. These descriptors are more difficult to calculate. In generating the 
fingerprints, the program assigns an initial code to each atom. The initial atom code is derived from the 
number of connections to the atom, the element type, atomic charge, and atomic mass. This corresponds 
to an ECFP with a neighborhood size of zero. These atom codes are then updated in an iterative manner 
to reflect the codes of each atoms neighbors. In the next iteration, a hashing scheme is employed to 
incorporate information from each atoms immediate neighbors. Each atoms new code now describes a 
molecular structure with a neighborhood size of one. This process is carried out for all atoms in the 
molecule. When the desired neighborhood size is reached, the process is complete and the set of all 
features is returned as the fingerprint. For the ECFPs employed in this paper, neighborhood sizes of two, 
four and six (ECFP 2, ECFP 4, ECFP 6) were used to generate the fingerprints. The resulting ECFPs can 
represent a much larger set of features than other fingerprints and contain a significant number of 
different structural units crucial for the molecular comparison, among the compounds. 
 
CONSTITUTIONAL DESCRIPTORS 
Natom Number of atoms 
MolWe Molecular Weight 
NRing Number of rings 
NArRg Numer of aromatic rings 
NRotB Number of rotatable bonds  
NHDon Number of H-bond donors  
NHAcc Number of H-bond acceptors  
CPSA DESCRIPTORS 
Msurf Molecular surface area 
Mpola Molecular polar surface area 
Msolu Molecular solubility 
AlogP Partition coefficient 
FRAGMENT/FINGERPRINT-BASED DESCRIPTORS 
ECP2, ECP4, ECP6 Extended-connectivity fingerprints (ECFP) 
EstCt Estate counts 
AlCnt AlogP2 Estate counts 
EstKy Estate keys 
MDLPK MDL public keys 
Table 2. Molecular descriptors used in this study. 
3. RESULTS 
A set of experiments has been carried out in order to test the validity of our initial hypothesis combining 
and refining VS results with the proposed CI methods. 
3.1 Activity prediction using Computational Intelligence methods  
NNET and SVM were trained with the previously described DUD datasets TK, MR and GPB. Molecular 
properties described in Table 2 were calculated for each molecule as described in the methods section.  
A k-fold cross-validation technique with k=5 was employed for NNET and SVM experiments. 
3.1.1 NNET 
A set of experiments has been developed to find the feed-forward neural network architecture that fits 
better to the problem of classification proposed. A combination of different number of neurons for the 
hidden layer has been tested with the different descriptors and datasets. We considered architectures with 
1, 2 and 3neurons in the hidden layer. Since results of combinations with more than 3 neurons did not 
improve the results, we decide to use the simplest option with 3 neurons due to its lower temporal cost for 
training phase. Results for AUC values are reported in Fig (4). 
.  
 
Figure 4. AUC values of the ROC curves obtained using NNET as described in section 2.2.1 for each 
property of Table 2 of the three different datasets GPB (blue), MR (red) and TK (yellow). Baseline for 
AUC=0.65 is also shown. The resulting AUC values for the combined properties described in Table 3 are 
also reported. 
 
 
3.1.2 SVM 
A set of experiments with different kernels has been developed to find the option with higher 
discrimination capacities between active and non-active compounds for each descriptor. More 
specifically, linear, polynomial, sigmoid and radial kernels has been tested with all the descriptors and 
datasets. Best results have been obtained with radial kernels and results obtained for AUC values are 
reported in Fig. (5). 
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 Figure 5. AUC values of the ROC curves obtained using SVM as described in section 2.2.1 for each 
property of Table 2 of the three different datasets GPB (blue), MR (red) and TK (yellow). Baseline for 
AUC=0.65 is also shown. The resulting AUC values for the combined properties described in Table 3 are 
also reported. 
 
4. DISCUSSION 
AUC values reported by both NNET and SVM depend clearly on the considered molecular property, and 
to a lesser extent, on the molecular dataset studied (GPB, MR, TK). The reason for the latter might be that 
main active compounds of these sets have similar structures, as shown in Fig. (6), consisting in small 
molecules with two or four rings, and also because they establish similar interactions with the protein, 
mainly based on hydrogen bond networks. 
We propose a threshold value of 0.65 for AUC in order to discriminate which properties are useful for 
active/inactive prediction. Properties that simultaneously yield AUC values higher than this threshold for 
all sets using both NNET and SVM are; AlCnt, E246, ECP2 and MDLPK, while properties that yield 
AUC values lower than threshold are mostly AlogP, MolWe, MPola, MSolu, MSurf, NArgRg, Natom, 
NHacc, NHDon, NRing, and NRotB. So it seems clear that the best option for discriminating among 
active and inactive compounds in these datasets is to use fingerprint-based descriptors and to avoid the 
use of constitutional and CPSA descriptors. This is reasonable since fingerprint descriptors take into 
account more details about the structure of molecules, being able to efficiently discriminate with more 
accuracy between active compounds and their decoys.  
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Next, we studied whether combination of properties could lead to improvements on the predictive 
capability of these CI methods. Therefore we combined properties that yielded the lowest AUC values, 
constitutional descriptors, and the properties that yielded the highest AUC values, so fingerprint based 
descriptors. Combinations used are described in Table 3 and AUC values obtained are reported in Figs. 
(4) and (5). In the case of combinations of constitutional descriptors, there is no clear improvement for 
either NNET or SVM, while for fingerprint combinations, average AUC values for the three datasets 
improve slightly.   
Finally, top obtained AUC values for datasets GPB, MR and TK correspond to properties EE246 (0.96), 
EstCt (0.87) and EAE246 (0.94) when using NNET, and AE246 (0.98), EstKy (0.98)and AlCnt (0.95) 
when using SVM.  
COMBINATIONS OF CONSTITUTIONAL DESCRIPTORS 
MNBH 
Molecular polar surface area (MPola)+ Number of rotatable 
bonds (NRotB) + Number of H-Bond acceptors (NHAcc) 
MNB 
Molecular polar surface area (MPola) + Number of rotatable 
bonds (NRotB) 
NBH 
Number of rotatable bonds (NRotB) + Number of H-Bond 
acceptors (NHAcc) 
MoN 
Molecular polar surface area (MPola) + Number of H-Bond 
acceptors (NHAcc) 
COMBINATIONS OF FRAGMENT/FINGERPRINT-BASED DESCRIPTORS 
EAE246 
Estate counts (EstCt) + AlogP2 Estate counts (AlCnt) + Extended-
connectivity fingerprints (ECFP) 
EA Estate counts (EstCt) + AlogP2 Estate counts (AlCnt)  
AE246 
AlogP2 Estate counts (AlCnt) + Extended-connectivity 
fingerprints (ECFP) 
EE246 
Estate counts (EstCt) + Extended-connectivity fingerprints 
(ECFP) 
Table 3. Combinations of molecular descriptors used in this study. 
 
 
Figure 6. Depiction of the molecular structure and protein-ligand interactions established by main active 
compounds from A) MR, B) TK, and C) GPB. 
 
Consequently, and taking into account information obtained by CI methods we can post-process docking 
results obtained by the scoring function of VS methods and neglect resulting compounds that are 
predicted as inactive. Then we can sort them by the final affinity value predicted by the VS scoring 
function for such cases and study visually the top ones.  
 
5. CONCLUSIONS 
In this work we have shown how the predictive capability of the VS methods can be improved using CI 
methods such as neural networks and support vector machines. It must be mentioned that CI approaches 
can only be used when experimental data for active and non-active compounds for a given protein is 
available. 
This methodology can be used to improve drug discovery, drug design, repurposing and therefore aid 
considerably in clinical research. In the next steps we want to extend our ideas to the application of 
unsupervised CI methods. 
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